SI9300223A - Immunogenic peptides/carbohydrate conjugates and process for their production - Google Patents

Immunogenic peptides/carbohydrate conjugates and process for their production Download PDF

Info

Publication number
SI9300223A
SI9300223A SI9300223A SI9300223A SI9300223A SI 9300223 A SI9300223 A SI 9300223A SI 9300223 A SI9300223 A SI 9300223A SI 9300223 A SI9300223 A SI 9300223A SI 9300223 A SI9300223 A SI 9300223A
Authority
SI
Slovenia
Prior art keywords
peptide
carbohydrate
cells
conjugate
component
Prior art date
Application number
SI9300223A
Other languages
English (en)
Slovenian (sl)
Inventor
Mikael Jondal
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9201338A external-priority patent/SE9201338D0/xx
Priority claimed from SE9202553A external-priority patent/SE9202553D0/xx
Priority claimed from SE9203897A external-priority patent/SE9203897D0/xx
Priority claimed from SE9301141A external-priority patent/SE9301141D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of SI9300223A publication Critical patent/SI9300223A/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI9300223A 1992-04-28 1993-04-28 Immunogenic peptides/carbohydrate conjugates and process for their production SI9300223A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9201338A SE9201338D0 (sv) 1992-04-28 1992-04-28 New active compounds
SE9202553A SE9202553D0 (sv) 1992-09-07 1992-09-07 New active compounds ii
SE9203897A SE9203897D0 (sv) 1992-12-23 1992-12-23 New active compounds iii
SE9301141A SE9301141D0 (sv) 1993-04-06 1993-04-06 New active compounds iv

Publications (1)

Publication Number Publication Date
SI9300223A true SI9300223A (en) 1994-03-31

Family

ID=27484749

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9300223A SI9300223A (en) 1992-04-28 1993-04-28 Immunogenic peptides/carbohydrate conjugates and process for their production

Country Status (19)

Country Link
US (2) US5807559A (fr)
EP (1) EP0675733B1 (fr)
JP (1) JPH07506358A (fr)
CN (1) CN1096032A (fr)
AT (1) ATE197903T1 (fr)
AU (1) AU676679B2 (fr)
CA (1) CA2134097A1 (fr)
DE (1) DE69329735T2 (fr)
DK (1) DK0675733T3 (fr)
ES (1) ES2155070T3 (fr)
GR (1) GR3035501T3 (fr)
IL (1) IL105503A (fr)
IS (1) IS4010A (fr)
MA (1) MA22885A1 (fr)
MY (1) MY108864A (fr)
PT (1) PT675733E (fr)
SI (1) SI9300223A (fr)
TN (1) TNSN93045A1 (fr)
WO (1) WO1993021948A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083929A (en) * 1991-05-06 2000-07-04 The Biomembrane Institute Extended type 1 chain glycosphingolipids as tumor-associated antigens
DE4436164A1 (de) * 1994-10-10 1996-04-11 Hoechst Ag Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US6841543B1 (en) 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
WO1998015286A1 (fr) * 1996-10-08 1998-04-16 La Jolla Institute For Allergy & Immunology Lymphocytes t a cytolyse specifique des glucides
US20070237785A1 (en) * 1997-03-27 2007-10-11 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
EP0969873B1 (fr) * 1997-03-27 2006-06-07 Institut Pasteur Conjugue antigenique multiple glucidique et peptidique, vaccin le contenant et son utilisation
US7550146B2 (en) * 1997-04-16 2009-06-23 Sloan-Kettering Institute For Cancer Research Glycopeptide conjugates and uses thereof
CA2286798C (fr) * 1997-04-16 2014-01-07 Sloan-Kettering Institute For Cancer Research Glycoconjugues a liaison alpha-o comprenant des epitopes (2.6)-st-groupes, procedes de preparation et utilisation de ces glycoconjugues
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
JP2002507577A (ja) * 1998-03-25 2002-03-12 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ 三量体抗原性ｏ−結合複合糖ペプチド、その製造方法及びその使用
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7402307B2 (en) * 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
EP1073667A2 (fr) * 1998-04-28 2001-02-07 Galenica Pharmaceuticals, Inc. Conjugues d'antigene et de polysaccharide
US20030091546A1 (en) * 1998-11-12 2003-05-15 Barber Jack R. Methods of suppressing immune response by gene therapy
US7824687B2 (en) 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
DE60027905T2 (de) 1999-08-20 2007-05-10 Sloan-Kettering Institute For Cancer Research Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
US7854934B2 (en) * 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
JP2007516157A (ja) * 2003-02-06 2007-06-21 トリペップ アクチ ボラゲット グリコシル化された抗原／抗体又はリガンド／受容体特異性交換体
WO2005077411A2 (fr) * 2004-02-10 2005-08-25 Innate Pharma Composition et procede pour le traitement de carcinome
CN101184780B (zh) 2005-05-05 2012-10-03 森馨香料公司 β-葡聚糖和甘露聚糖的制备
WO2007073486A2 (fr) 2005-12-20 2007-06-28 Duke University Procedes et compositions pour l'administration d'agents actifs a proprietes pharmacologiques ameliorees
EP2391635B1 (fr) 2009-01-28 2017-04-26 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
AU2011232435B2 (en) 2010-03-23 2016-01-28 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
EP2500033A1 (fr) 2011-03-17 2012-09-19 Institut Pasteur Procédé pour la préparation de plusieurs conjugués de carbohydrate de glycopeptide d'antigène
JP2014524796A (ja) 2011-06-28 2014-09-25 イノビオ ファーマシューティカルズ，インコーポレイティド 低侵襲表皮電気穿孔装置
EP2606897A1 (fr) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Procédés et compositions pour le traitement des maladies causées par les virus enveloppés
CA3069527A1 (fr) 2017-07-12 2019-01-17 The Board Of Trustees Of The Leland Stanford Junior University Compositions et methodes pour le traitement de cancers presentant une mutation h3k27m

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2004744B (en) * 1977-09-28 1982-05-26 Sanderson A R Immonulogical preparations
CA1335883C (fr) * 1986-07-08 1995-06-13 Bryan Michael Longenecker Stimulation de la reponse immunitaire cellulaire
ATE109008T1 (de) * 1988-02-01 1994-08-15 Praxis Biolog Inc T-zellen-epitope als träger für einen konjugierten impfstoff.
JPH03504493A (ja) * 1988-02-12 1991-10-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞性免疫の発生及び操作のための合成ペプチドの使用
US5229289A (en) * 1988-03-11 1993-07-20 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
CA1337403C (fr) * 1988-03-28 1995-10-24 Biomembrane Institute (The) Methodes de production d'anticorps et induction de reponses immunitaires aux gangliosides associes aux tumeurs par immunisation avec des lactones de gangliosides
JPH04506662A (ja) * 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
WO1991003494A1 (fr) * 1989-08-28 1991-03-21 Pierce Chemical Company Porteurs cationises pour la production d'immunogenes
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.

Also Published As

Publication number Publication date
JPH07506358A (ja) 1995-07-13
PT675733E (pt) 2001-05-31
AU676679B2 (en) 1997-03-20
US5807559A (en) 1998-09-15
CN1096032A (zh) 1994-12-07
US6033669A (en) 2000-03-07
WO1993021948A1 (fr) 1993-11-11
MA22885A1 (fr) 1993-12-31
IL105503A0 (en) 1993-08-18
MY108864A (en) 1996-11-30
TNSN93045A1 (fr) 1994-03-17
DE69329735T2 (de) 2001-08-02
CA2134097A1 (fr) 1993-11-11
ES2155070T3 (es) 2001-05-01
IS4010A (is) 1993-10-29
EP0675733B1 (fr) 2000-12-06
ATE197903T1 (de) 2000-12-15
DE69329735D1 (de) 2001-01-11
AU4274693A (en) 1993-11-29
DK0675733T3 (da) 2001-05-07
GR3035501T3 (en) 2001-06-29
IL105503A (en) 1999-05-09
EP0675733A1 (fr) 1995-10-11

Similar Documents

Publication Publication Date Title
SI9300223A (en) Immunogenic peptides/carbohydrate conjugates and process for their production
Yin et al. Recent development in carbohydrate based anticancer vaccines
US8357777B2 (en) Enhanced immunogenicity of tumor associated antigens by addition of αgal epitopes
Abdel‐Aal et al. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist
Danishefsky et al. From the laboratory to the clinic: a retrospective on fully synthetic carbohydrate‐based anticancer vaccines
Singhal et al. Induction of α-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice
Karmakar et al. Synthesis of a liposomal MUC1 glycopeptide-based immunotherapeutic and evaluation of the effect of L-rhamnose targeting on cellular immune responses
Sarkar et al. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes
Becker et al. Synthetic glycopeptides from the mucin family as potential tools in cancer immunotherapy
Hossain et al. Augmenting vaccine immunogenicity through the use of natural human anti-rhamnose antibodies
US20070275019A9 (en) Vaccines directed to cancer-associated carbohydrate antigens
Reintjens et al. Self-adjuvanting cancer vaccines from conjugation-ready lipid A analogues and synthetic long peptides
US20130149331A1 (en) Rhamnose and forssman conjugated immunogenic agents
Rashidijahanabad et al. Stereoselective Synthesis of Sialyl Lewisa Antigen and the Effective Anticancer Activity of Its Bacteriophage Qβ Conjugate as an Anticancer Vaccine
Warren et al. Synthetic glycopeptide-based vaccines
Marqvorsen et al. Going native: synthesis of glycoproteins and glycopeptides via native linkages to study glycan-specific roles in the immune system
US20160022826A1 (en) Carbohydrate-modified glycoproteins and uses thereof
Franco Glycoconjugates as vaccines for cancer immunotherapy: clinical trials and future directions
US20220233668A1 (en) Glycopeptide vaccine
Liu et al. Design, synthesis, and preliminary immunological studies of MUC1-based antitumor vaccines adjuvanted with R-and S-FSL-1
Zhang et al. Ganglioside GM3-based anticancer vaccines: Reviewing the mechanism and current strategies
KR20060125675A (ko) 항원 전달 시스템
EP1117432A1 (fr) Vaccins aux hydrates de carbone contre les maladies virales